Skip to main content

Table 2 Multivariate hazard ratios, confidence intervals, and p values

From: Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

  Hazard Ratio
Estimate 95% CI p value**
Treatment Groups
SRS* reference
Surgery + SRS 0.68 0.49-0.94 0.020
WBRT + SRS 0.99 0.93-1.05 0.660
Surgery + WBRT + SRS 0.79 0.61-1.02 0.070
WBRT 1.94 1.37-2.73 <0.001
Surgery + WBRT 1.04 0.76-1.43 0.800
Age at diagnosis
<65* reference
≥65 1.21 0.91-1.62 0.190
ECOG-PS
0* reference
1 1.07 0.58-1.95 0.830
2 1.67 1.02-2.72 0.040
3 4.58 4.28-4.91 <0.001
4 11.26 5.98-21.2 <0.001
Primary Tumor Histology
NSCLC* reference
SCLC 1.11 0.97-1.26 0.130
Breast 0.87 0.78-0.96 <0.001
Melanoma and Renal-cell 1.17 1.06-1.3 <0.001
Other 1.41 0.95-2.1 0.080
  1. ECOG-PS = Eastern Cooperative Oncology Group-Performance Status; NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; SRS = stereotactic radiosurgery; WBRT = whole brain radiation therapy
  2. * Reference group against which other groups' survival experience are compared
  3. ** p value for test if groups' survival experience is same as reference group